Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016

10.03.2016 | Oncology

Trabeculectomy in patients with uveal melanoma after proton beam therapy

verfasst von: Aline I. Riechardt, Dino Cordini, Matus Rehak, Annette Hager, Ira Seibel, Alexander Böker, Enken Gundlach, Jens Heufelder, Antonia M. Joussen

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Retrospective evaluation of intraocular pressure, use of topical and systemic anti-glaucoma medication, secondary complications, local tumor control and survival in patients treated with trabeculectomy for the regulation of the intraocular pressure (IOP) after proton beam therapy for uveal melanoma.

Methods

In this retrospective clinical case series we evaluated the follow-up of 15 patients receiving a trabeculectomy as surgical treatment if the IOP could not be lowered adequately by medications or laser surgery. All patients had received proton beam therapy for uveal melanoma at the Helmholtz-Zentrum Berlin between 1998 and 2010.

Results

The median IOP decreased significantly from 35 mmHg ± 8.8 before TE to 16 mmHg ± 8.2 (=52.3 %) six months after TE (Wilcoxon-Mann–Whitney-U Test, p<0.01). None of the patients needed any glaucoma medication six months after trabeculectomy. Two patients developed local recurrence during follow-up, which were independent of the trabeculectomy. One patient had to be enucleated due to intractable pain and suspected remaining tumor activity. One patient died due to metastasis.

Conclusions

Trabeculectomy is an option in intractable glaucoma in patients with uveal melanoma after proton beam therapy in single cases. Secondary interventions are common. Inoculation metastases are possible. Secure local tumor control must be a prerequisite for filtrating operations.
Literatur
1.
Zurück zum Zitat Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881–1885CrossRefPubMed Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881–1885CrossRefPubMed
2.
Zurück zum Zitat Riechardt AI, Cordini D, Willerding G, Georgieva I, Weber A, Seibel I, Lakotka N, Bechrakis NE, Foerster MH, Moser L, Joussen AM (2014) Proton beam therapy of parapapillary choroidal melanoma. Am J Ophthalmol 157:1258–1265CrossRefPubMed Riechardt AI, Cordini D, Willerding G, Georgieva I, Weber A, Seibel I, Lakotka N, Bechrakis NE, Foerster MH, Moser L, Joussen AM (2014) Proton beam therapy of parapapillary choroidal melanoma. Am J Ophthalmol 157:1258–1265CrossRefPubMed
3.
Zurück zum Zitat European Glaucoma Society (2014) Treatment options for glaucoma due to intraocular tumour. In: Terminology and Guidelines for Glaucoma, 4th edn. PubliComm, Savona, Italy, p 95 European Glaucoma Society (2014) Treatment options for glaucoma due to intraocular tumour. In: Terminology and Guidelines for Glaucoma, 4th edn. PubliComm, Savona, Italy, p 95
4.
Zurück zum Zitat Wanner JB, Pasquale LR (2006) Glaucomas secondary to intraocular melanomas. Semin Ophthalmol 21:181–189CrossRefPubMed Wanner JB, Pasquale LR (2006) Glaucomas secondary to intraocular melanomas. Semin Ophthalmol 21:181–189CrossRefPubMed
5.
Zurück zum Zitat Vaswani RS, Bollinger K, Singh A, Singh AD (2014) Tumor-Associated Glaucoma. In: Singh AD, Bertil D (eds) Clinical ophthalmic oncology, Basic principles and diagnostic techniques. Springer, Berlin Heidelberg, pp 151–159CrossRef Vaswani RS, Bollinger K, Singh A, Singh AD (2014) Tumor-Associated Glaucoma. In: Singh AD, Bertil D (eds) Clinical ophthalmic oncology, Basic principles and diagnostic techniques. Springer, Berlin Heidelberg, pp 151–159CrossRef
6.
Zurück zum Zitat Pasternak S, Erwenne CM, Nicolela MT (2005) Subconjunctival spread of ciliary body melanoma after glaucoma filtering surgery: a clinicopathological case report. Can J Ophthalmol 40:69–71CrossRefPubMed Pasternak S, Erwenne CM, Nicolela MT (2005) Subconjunctival spread of ciliary body melanoma after glaucoma filtering surgery: a clinicopathological case report. Can J Ophthalmol 40:69–71CrossRefPubMed
7.
Zurück zum Zitat Grossniklaus HE, Brown RH, Stulting D, Blasberg RD (1990) Iris melanoma seeding through trabeculectomy site. Arch Ophthalmol 108:1287–1290CrossRefPubMed Grossniklaus HE, Brown RH, Stulting D, Blasberg RD (1990) Iris melanoma seeding through trabeculectomy site. Arch Ophthalmol 108:1287–1290CrossRefPubMed
8.
Zurück zum Zitat Sharkawi E, Oleszczuk JD, Bergin C, Zografos L (2012) Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy. Br J Ophthalmol 96:1104–1107CrossRefPubMed Sharkawi E, Oleszczuk JD, Bergin C, Zografos L (2012) Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy. Br J Ophthalmol 96:1104–1107CrossRefPubMed
9.
Zurück zum Zitat Höcht S, Bechrakis NE, Nausner M, Kreusel KM, Kluge H, Heese J, Heufelder J, Cordini D, Homeyer H, Fuchs H, Martus P, Foerster MH, Wiegel T, Hinkelbein W (2004) Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. Strahlenther Onkol 180:419–424CrossRefPubMed Höcht S, Bechrakis NE, Nausner M, Kreusel KM, Kluge H, Heese J, Heufelder J, Cordini D, Homeyer H, Fuchs H, Martus P, Foerster MH, Wiegel T, Hinkelbein W (2004) Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. Strahlenther Onkol 180:419–424CrossRefPubMed
10.
11.
Zurück zum Zitat Pfeiffer K, Dobler B, Rethfeldt C, Schlegel W, Bendl R (2000) OCTOPUS, a planning tool for proton therapy of eye tumour. In: Schlegel W, Bortfeld T (eds) The use of Computers in Radiation Therapy. Springer, Berlin Heidelberg, pp 329–331CrossRef Pfeiffer K, Dobler B, Rethfeldt C, Schlegel W, Bendl R (2000) OCTOPUS, a planning tool for proton therapy of eye tumour. In: Schlegel W, Bortfeld T (eds) The use of Computers in Radiation Therapy. Springer, Berlin Heidelberg, pp 329–331CrossRef
12.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM Classification of Malignant Tumours, 7th ed. Wiley-Blackwell, Oxford Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM Classification of Malignant Tumours, 7th ed. Wiley-Blackwell, Oxford
13.
Zurück zum Zitat Piirtola A, Puska P, Kivelä T (2014) Red laser cyclophotocoagulation in the treatment of secondary glaucoma in eyes with uveal melanoma. J Glaucoma 23:50–55CrossRefPubMed Piirtola A, Puska P, Kivelä T (2014) Red laser cyclophotocoagulation in the treatment of secondary glaucoma in eyes with uveal melanoma. J Glaucoma 23:50–55CrossRefPubMed
14.
Zurück zum Zitat Raivio VE, Immonen IJR, Puska PM (2007) Transscleral red-laser cyclophotocoagulation combined with limited anterior retinal cryocoagulation in neovascular glaucoma. Acta Ophthalmol Scand 85:60–66CrossRefPubMed Raivio VE, Immonen IJR, Puska PM (2007) Transscleral red-laser cyclophotocoagulation combined with limited anterior retinal cryocoagulation in neovascular glaucoma. Acta Ophthalmol Scand 85:60–66CrossRefPubMed
15.
Zurück zum Zitat Jea SY, Francis BA, Vakili G, Filippopoulos T, Rhee DJ (2012) Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthalmology 119:36–42CrossRefPubMed Jea SY, Francis BA, Vakili G, Filippopoulos T, Rhee DJ (2012) Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthalmology 119:36–42CrossRefPubMed
16.
Zurück zum Zitat Fröhlich SJ, Mueller AJ, Kampik A (2003) Relative contraindication of latanoprost in iris tumors with secondary glaucoma [Article in German]. Ophthalmologe 100:133–638CrossRef Fröhlich SJ, Mueller AJ, Kampik A (2003) Relative contraindication of latanoprost in iris tumors with secondary glaucoma [Article in German]. Ophthalmologe 100:133–638CrossRef
17.
Zurück zum Zitat Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, Bechrakis N, Heufelder J, Moser L, Joussen AM (2014) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. doi:10.1136/bjophthalmol-2014-305174 PubMed Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, Bechrakis N, Heufelder J, Moser L, Joussen AM (2014) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. doi:10.​1136/​bjophthalmol-2014-305174 PubMed
18.
Zurück zum Zitat Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II (2013) The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology 120:2232–2240CrossRefPubMed Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II (2013) The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology 120:2232–2240CrossRefPubMed
19.
Zurück zum Zitat Tay E, Cree IA, Hungerford J, Franks W (2009) Recurrence of treated ciliary body melanoma following trabeculectomy. Clin Exp Ophthalmol 37:503–505CrossRef Tay E, Cree IA, Hungerford J, Franks W (2009) Recurrence of treated ciliary body melanoma following trabeculectomy. Clin Exp Ophthalmol 37:503–505CrossRef
20.
Zurück zum Zitat Bechrakis NE, Petousis V, Willerding G, Krause L, Wachtlin J, Stroux A, Foerster MH (2010) Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 94:460–466CrossRefPubMed Bechrakis NE, Petousis V, Willerding G, Krause L, Wachtlin J, Stroux A, Foerster MH (2010) Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 94:460–466CrossRefPubMed
21.
Zurück zum Zitat Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Schefler AC, Murray TG, Kivelä T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE (2012) Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol 130:57–64CrossRefPubMed Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Schefler AC, Murray TG, Kivelä T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE (2012) Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol 130:57–64CrossRefPubMed
22.
Zurück zum Zitat Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A (2001) Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172–178CrossRefPubMed Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A (2001) Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172–178CrossRefPubMed
Metadaten
Titel
Trabeculectomy in patients with uveal melanoma after proton beam therapy
verfasst von
Aline I. Riechardt
Dino Cordini
Matus Rehak
Annette Hager
Ira Seibel
Alexander Böker
Enken Gundlach
Jens Heufelder
Antonia M. Joussen
Publikationsdatum
10.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2016
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3310-5

Weitere Artikel der Ausgabe 7/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.